Sign In
Buy INMB
$1.32
-0.1000 (-7.04%)
At Close: Jun 03, 2026
INmune Bio A No-Brainer Investment
05:44pm, Wednesday, 13'th Oct 2021
GameStop stock continues to defy the Street logic. Its fans are willing to stick around with Ryan Cohen & Co. for the long term. Matt Furlong & the team did not announce anything substantial on its re
INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series
04:00pm, Monday, 27'th Sep 2021
Boca Raton, FL, Sept. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient
INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences
04:00pm, Monday, 20'th Sep 2021
BOCA RATON, Florida, Sept. 20, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the
INMB Stock: Explanation For Over 30% Increase This Week
10:56am, Thursday, 02'nd Sep 2021
The stock price of INmune Bio Inc (NASDAQ: INMB) increased by over 30% this week. This is why it happened.
Why Are Shares Of INmune Bio Trading Higher Wednesday Afternoon?
04:45pm, Wednesday, 01'st Sep 2021
INmune Bio, Inc. (NASDAQ: INMB) shares traded higher Wednesday afternoon following data out of a trial for the company's Alzheimer's drug candidate. The company said its selective dominant-negative tu
Alzheimer's Patients Treated with INmune Bio's XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination
04:00pm, Wednesday, 01'st Sep 2021
XPro™ treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an improvement in an imaging biomarker of myelination. XPro™ treatment shows statistically signif
First positive clinical confirmation of in vivo NK response, mirroring in vitro data
Our Bullish Take On INmune Bio's Drug Pipeline
10:57pm, Wednesday, 11'th Aug 2021
Our Bullish Take On INmune Bio's Drug Pipeline
INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
09:00am, Tuesday, 10'th Aug 2021
BOCA RATON, Florida, Aug. 10, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the pat
INmune Bio, Inc. (INMB) CEO David Moss on Q2 2021 Results - Earnings Call Transcript
09:30pm, Saturday, 07'th Aug 2021
INmune Bio, Inc. (INMB) CEO David Moss on Q2 2021 Results - Earnings Call Transcript
INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference
08:15am, Thursday, 05'th Aug 2021
LA JOLLA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the pat
INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update
04:20pm, Wednesday, 04'th Aug 2021
Company to host conference call today, August 4, at 4:30pm ET Company to host conference call today, August 4, at 4:30pm ET
INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer's Disease Clinical Trial and New Phase 1b AD Biomarker Data
08:30am, Monday, 26'th Jul 2021
Phase 2 study of XPro TM will be a six -month , blinded , randomized , placebo-controlled trial in 168 patients with m ild A lzheimer's disease and biomarkers of inflammation .
INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments
11:53am, Thursday, 22'nd Jul 2021
AMSTERDAM, July 22, 2021 /PRNewswire/ -- LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, has
INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer's Association International Conference 2021
08:30am, Monday, 19'th Jul 2021
Company to introduce design of upcoming Phase 2 study of XPro1595 in Alzheimer's disease, which is expected to commence this year
